Back to top

Analyst Blog

MedAssets, Inc. (MDAS - Snapshot Report) recently announced the renewal of its multi-year agreement with Kaiser Permanente, the largest healthcare provider in California. The agreement entails MedAssets to continue as the exclusive group purchasing organization for Kaiser Permanente.

The announcement triggered a rise of 3.8% in MedAssets’ share price in the trading session, with the stock closing at $21.11 on Jan 15.

Per the deal, MedAssets will provide Strategic Sourcing and Spend Analytics solutions to Kaiser Permanente. Both Strategic Sourcing and Spend Analytics are web-based  business intelligence tools designed to facilitate improved business decisions.

These innovative business solutions primarily cater to the supply chain management activities within a business. This functional area is critical for achieving high levels of operational efficiency.

Strategic Sourcing and Spend Analytics support the cost-reduction initiatives and improve contract negotiations for a company.

Such innovative and effective business solutions from MedAssets are fast gaining popularity. This is validated by the company’s renewal of a couple of deals in the recent past. Allina Health, a not-for-profit health system, has extended its prior agreement with MedAssets to align hospital and physician reimbursement strategies more efficiently across its own healthcare domain.

Similarly, MedAssets also got its contract renewed with Advocate Health Care – a 12-hospital, 3,300-bed health system, as part of its performance improvement relationship that aimed to improve operational efficiencies and standards of care at the latter.

Likewise, California-based Marin General Hospital (MGH) also appointed MedAssets for a comprehensive cost and operational management improvement program.

The abovementioned contract renewals assure the company of a steady flow of revenues in the forthcoming quarters. MedAssets provided its guidance for 2013, expecting revenues to be in the range of $671-$677 million. The Zacks Consensus Estimate for the same is pegged at $675 million.

We believe companies like MedAssets are poised to gain in the long run now that healthcare providers are striving to realize more financial and operational gains while simultaneously delivering improved customer service.

Currently, MedAssets carries a Zacks Rank #3 (Hold).

Investors interested in the medical services industry can consider better-ranked stocks like Air Methods Corp. (AIRM - Snapshot Report), Envision Healthcare Holdings, Inc. (EVHC - Snapshot Report) and Charles River Laboratories International, Inc. (CRL - Snapshot Report). All these stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
THE PANTRY… PTRY 21.27 +3.30%
ERBA DIAGNO… ERB 2.99 +2.75%
WILLDAN GRO… WLDN 11.76 +2.08%
SANCHEZ ENE… SN 33.98 +2.07%
INTEL CP INTC 35.13 +1.74%